ClinicalTrials.gg
CompletedNCT03329911Updated Sep 14, 2021Results posted

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

A Phase 3 interventional study of EU Avastin® and BAT1706 in Non-squamous Non-small Cell Lung Cancer, sponsored by Bio-Thera Solutions. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Bio-Thera Solutions · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
651
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
129th of 1,594
651 · median 100
Started
2017
with 82 others
Phase 3
366 of 1,881
104 open now
Registered
419th of 1,881
by date

Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 129th largest by enrollment of the 1,594 interventional ones that give a count, is one of 83 that started in 2017, is one of 366 in phase 3, and was the 419th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®.

03

Conditions studied

  • Non-squamous Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stage IV nsNSCLC or recurrent disease (any Stage at initial diagnosis) no longer amenable to curative surgery or local therapy ( or cytologically confirmed).
  2. No prior systemic therapy for disease. Prior systemic therapy and/or radiotherapy for locally advanced disease is permitted if completed ≥ 6 months prior to randomization.
  3. Tumors without activating EGFR or ALK mutation. Patients with unknown mutation status or known activating EGFR or ALK mutation may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center.
  4. At least one measurable target lesion according to 1.1 (Appendix 13.4) as confirmed by CIR; bone only and brain-only metastases are not allowed. Lesions previously treated with radiotherapy are non-target lesion.
  5. performance status of 0 or 1 and > 3 months based on Investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of small cell carcinoma of the lung, mixed predominant squamous cell carcinoma of the lung, NSCLC not otherwise specified.
  2. Tumor cavitation, tumor invading into large blood vessels or close to large vessels with an increased risk of bleeding, according to Investigator's judgment.
  3. Prior therapy with monoclonal antibodies or small molecule inhibitors against VEGF or VEGFR, including Avastin®.
  4. Prior systemic therapy for disease.
  5. Prior systemic anticancer therapy, or radiotherapy for locally advanced nsNSCLC if completed \< 6 months prior to screening.
  6. Previous other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre invasive cancer of the cervix.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
651 participants (actual)

Study arms

  • Active comparator
    EU Avastin®

    Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months. Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles

    Drug: EU Avastin® · Drug: Paclitaxel · Drug: carboplatin

  • Experimental
    BAT1706

    BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months. Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles

    Drug: BAT1706 · Drug: Paclitaxel · Drug: carboplatin

Interventions

  • DrugEU Avastin®

    100 mg/4 mL

  • 100 mg/4 mL

  • 200 mg/m²

  • target area under the curve \[AUC\] 6 mg/mL•minute

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data: CR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)

    Time frame: Week 18

Secondary outcomes

  1. Progression Free Survival Rate

    Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.

    Time frame: 8 months,1 year and 2 years

  2. Progression Free Survival Time

    Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.

    Time frame: 8 months,1 year and 2 years

  3. Overall Survival Rate

    Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.

    Time frame: 8 months,1 year and 2 years

  4. Overall Survival Time

    Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.

    Time frame: 8 months,1 year and 2 years

  5. Overall Response Rate

    ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.

    Time frame: Week 6 and Week 12

  6. Duration of Response

    Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.

    Time frame: 8 months

Other outcomes

  1. Plasma Level of Anti Drug Antibodies (ADA) and Neutralizing Anti-drug Antibodies (NADA) Correlated With Bevacizumab Plasma Level

    Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level

    Time frame: 12 months

  2. Bevacizumab Plasma Exposure Following Treatments of BAT1706 or EU Avastin®

    Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®

    Time frame: 12 months

07

Results

Posted Sep 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneEU Avastin®BAT1706
Started326325
Completed209222
Not completed117103

Outcome measures

PrimaryOverall Response Rate

The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data: CR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)

Time frame:
Week 18
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsEU Avastin®BAT1706
Overall Response Rate156145
SecondaryProgression Free Survival Rate

Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.

Time frame:
8 months,1 year and 2 years

Results for this outcome have not been posted.

SecondaryProgression Free Survival Time

Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.

Time frame:
8 months,1 year and 2 years

Results for this outcome have not been posted.

SecondaryOverall Survival Rate

Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.

Time frame:
8 months,1 year and 2 years

Results for this outcome have not been posted.

SecondaryOverall Survival Time

Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.

Time frame:
8 months,1 year and 2 years

Results for this outcome have not been posted.

SecondaryOverall Response Rate

ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.

Time frame:
Week 6 and Week 12

Results for this outcome have not been posted.

SecondaryDuration of Response

Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.

Time frame:
8 months

Results for this outcome have not been posted.

Other pre-specifiedPlasma Level of Anti Drug Antibodies (ADA) and Neutralizing Anti-drug Antibodies (NADA) Correlated With Bevacizumab Plasma Level

Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level

Time frame:
12 months

Results for this outcome have not been posted.

Other pre-specifiedBevacizumab Plasma Exposure Following Treatments of BAT1706 or EU Avastin®

Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®

Time frame:
12 months

Results for this outcome have not been posted.

Adverse events

Collected over From the start of the first study medication administration until 28 days after discontinuation/completion of the study medication or up to Week 53 after randomization- All AEs, regardless of relationship to the study medication/study procedures. During the LTE study, only adverse events of special interest (AESIs) and SAEs until 28 days after the subject's last dose will be collected.. Non-serious events are listed at a 0.3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EU Avastin®4/324 (1.2%)119/324 (36.7%)8/324 (2.5%)
BAT17067/325 (2.2%)119/325 (36.6%)9/325 (2.8%)
Most frequent serious events
Most frequent serious events
EventEU Avastin®BAT1706
Blood and lymphatic system disordersBlood and lymphatic system disorders46/32431/325
Infections and infestationsInfections and infestations22/32427/325
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders19/32421/325
Gastrointestinal disordersGeneral disorders12/32412/325
Cardiac disordersCardiac disorders4/32411/325
Vascular disordersVascular disorders8/3245/325
General disorders and administration site conditionsGastrointestinal disorders4/3248/325
Nervous system disordersNervous system disorders4/3244/325
Most frequent other events
Most frequent other events
EventEU Avastin®BAT1706
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders3/3245/325
Renal and urinary disordersRenal and urinary disorders2/3243/325
Neoplasms benign, malignant and unspecified (inclcysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)2/3240/325
HepatobiliarydisordersHepatobiliary disorders1/3241/325

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EU Avastin®BAT1706Total
<=18 years000
Between 18 and 65 years208233441
>=65 years11892210
Age, Continuous
Age, Continuous(years)EU Avastin®BAT1706Total
Median60 (26 to 88)61 (27 to 84)61 (26 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)EU Avastin®BAT1706Total
Female9797194
Male229228457
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EU Avastin®BAT1706Total
American Indian or Alaska Native131124
Asian140141281
Native Hawaiian or Other Pacific Islander101
Black or African American112
White171172343
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)EU Avastin®BAT1706Total
Turkey6764131
China139140279
Ukraine98102200
South Africa628
Mexico161733
08

Study locations

5 sites
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • Clinical Medical Research S.C.
    Orizaba, 94300, Mexico
  • National Hospital Oncology
    Bloemfontein, 9301, South Africa
  • Baskent University Ankara Hospital
    Ankara, 6000, Turkey
  • CI Kryvyi Rih Oncological Dispensary of DRC
    Kryvyi Rih, 53213, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2019, 24 months.

Results were first posted in Sep 2021, 1 year 10 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 24 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Nov 6, 2017
StartActual
Oct 20, 2017
Primary completionActual
Nov 5, 2019
CompletionActual
May 27, 2021
Results first posted
Sep 13, 2021
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03329911
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 20, 2017
Primary completion
Nov 5, 2019
Completion
May 27, 2021
Results posted
Sep 13, 2021
Last update
Sep 14, 2021

Study contacts

Shengfeng Li
study director · Sponsor GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAT1706

Start the discussion